Sex: U
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia, Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement); Mild injection site redness; Moderate injection site swelling; Moderate fever (101.3 to 102 °F); Moderate fatigue with some interference with activity; Mild muscle pain and no interference with activity; Joint pain and no interference with activity; Headache that interfered with activity OR required repeated use of a nonprescription pain reliever; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling) and PYREXIA (Moderate fever (101.3 to 102 °F)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling), PYREXIA (Moderate fever (101.3 to 102 °F)), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Mild muscle pain and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity) and HEADACHE (Headache that interfered with activity OR required repeated use of a nonprescription pain reliever). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling), PYREXIA (Moderate fever (101.3 to 102 °F)), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Mild muscle pain and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity) and HEADACHE (Headache that interfered with activity OR required repeated use of a nonprescription pain reliever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Moderate fever (101.3 to 102 °F).         Concomitant medications were not reported.   Patient had experienced the events anytime during the 2 days after your COVID-19 vaccination, which occurred on Monday, Dec 18, 2023 and Tuesday, Dec 19, 2023. Patient had headache that interfered with activity or required repeated use of a nonprescription pain reliever.  No treatment medication was provided by the reporter.  The Subject ID was reported as 5471992. The Agency Subject ID was reported as 39235-71735.   This case was linked to US-MODERNATX, INC.-MOD-2024-756177 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756177:same reporter